Neoantigen based immuno-oncology therapies are proving promising, but neoantigen identification and production are bottlenecks to boosting efficacy. In this webcast, Dr. Samantha Zaroff of GenScript and Dr. Julie Rumble of Cayman Chemical will review the use of neoantigen peptides in personalized cancer treatment and share techniques for predicting and producing difficult neoantigen peptides.
You will learn:
- Why neoantigens are so difficult to identify and produce
- How Cayman Chemical’s immunopeptidome profiling enhances neoantigen discovery over bioinformatics prediction tools
- How GenScript’s proprietary technologies for neoantigen production can substantially increase peptide synthesis rate